[go: up one dir, main page]

MX2009003562A - Ensayo elisa para la deteccion de vegf. - Google Patents

Ensayo elisa para la deteccion de vegf.

Info

Publication number
MX2009003562A
MX2009003562A MX2009003562A MX2009003562A MX2009003562A MX 2009003562 A MX2009003562 A MX 2009003562A MX 2009003562 A MX2009003562 A MX 2009003562A MX 2009003562 A MX2009003562 A MX 2009003562A MX 2009003562 A MX2009003562 A MX 2009003562A
Authority
MX
Mexico
Prior art keywords
vegf
elisa test
diagnostic
index
vegf detection
Prior art date
Application number
MX2009003562A
Other languages
English (en)
Inventor
Yu-Ju G Meng
Kyu H Hong
Johnny Gutierrez
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009003562A publication Critical patent/MX2009003562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G01N33/57595—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La actividad del factor de crecimiento endotelial vascular (VEGF) en el torrente sanguíneo de un paciente o en otra muestra biológica puede servir como índice de diagnóstico y pronóstico para el cáncer, diabetes, afecciones cardíacas y otras patologías. Los métodos de ensayo ELISA de tipo "sándwich" que utilizan anticuerpos y los kits de detección de VEGF como antígeno se proporcionan para detectar los tipos de niveles de VEGF en muestras biológicas de modelos animales y pacientes humanos y pueden ser utilizados como índice de diagnóstico y pronóstico.
MX2009003562A 2006-10-04 2007-10-03 Ensayo elisa para la deteccion de vegf. MX2009003562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82820306P 2006-10-04 2006-10-04
PCT/US2007/080310 WO2008060777A2 (en) 2006-10-04 2007-10-03 Elisa for vegf

Publications (1)

Publication Number Publication Date
MX2009003562A true MX2009003562A (es) 2009-04-15

Family

ID=39301650

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009003562A MX2009003562A (es) 2006-10-04 2007-10-03 Ensayo elisa para la deteccion de vegf.
MX2014011461A MX342791B (es) 2006-10-04 2009-04-02 Ensayo elisa para la detección de vegf.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014011461A MX342791B (es) 2006-10-04 2009-04-02 Ensayo elisa para la detección de vegf.

Country Status (24)

Country Link
US (5) US20080227119A1 (es)
EP (3) EP2457929B1 (es)
JP (1) JP6025294B2 (es)
KR (2) KR101720887B1 (es)
CN (2) CN101523220B (es)
AR (2) AR063125A1 (es)
AU (1) AU2007319654B2 (es)
BR (1) BRPI0715239A2 (es)
CA (1) CA2663012C (es)
DK (2) DK2069798T3 (es)
ES (2) ES2584322T3 (es)
HR (1) HRP20140675T1 (es)
HU (1) HUE030082T2 (es)
IL (1) IL197374A (es)
MX (2) MX2009003562A (es)
NZ (1) NZ613646A (es)
PL (2) PL2069798T3 (es)
PT (1) PT2069798E (es)
RS (1) RS53387B (es)
RU (2) RU2517301C2 (es)
SI (2) SI2069798T1 (es)
TW (2) TWI541251B (es)
WO (1) WO2008060777A2 (es)
ZA (1) ZA200901518B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
CN101523220B (zh) 2006-10-04 2016-09-21 健泰科生物技术公司 针对vegf的elisa
WO2011031986A1 (en) 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
WO2012010550A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130126576A (ko) * 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
CN102207504A (zh) * 2011-03-23 2011-10-05 北京华创远航科技有限公司 一种酶联检测试剂盒及其制备方法
CN102435743B (zh) * 2011-09-15 2014-10-15 北京健平九星生物医药科技有限公司 一种酶联检测试剂盒及其制备方法
CN102426240B (zh) * 2011-09-19 2014-10-15 北京健平金星生物科技有限公司 一种酶联检测试剂盒及其制备方法
KR20140099277A (ko) * 2011-12-19 2014-08-11 에프. 호프만-라 로슈 아게 다중특이적 결합제의 자유 결합 파트너의 검출 방법
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
CN104105966B (zh) * 2012-02-01 2016-10-26 弗·哈夫曼-拉罗切有限公司 用于检测多特异性结合物的结合搭档的方法
CN102645530B (zh) * 2012-04-06 2014-06-18 上海蓝怡科技有限公司 甲状腺素酶联免疫体外诊断试剂盒中酶结合物稀释液的制备方法
CN104471397B (zh) 2012-07-13 2018-03-23 弗·哈夫曼-拉罗切有限公司 用于检测多特异性结合物的方法
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
AU2014336016B2 (en) 2013-10-17 2019-12-19 Sartar Therapeutics Ltd Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
RU2589286C1 (ru) * 2015-02-03 2016-07-10 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования исхода заболевания у больных метастатическим раком почки
RU2622005C2 (ru) * 2015-11-24 2017-06-08 Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) СПОСОБ ПОЛУЧЕНИЯ СЕЛЕКТИВНОГО ИММУНОСОРБЕНТА ДЛЯ УДАЛЕНИЯ АНТИТЕЛ-IgG К ДЕСМОГЛЕИНУ 3 ТИПА ИЗ СЫВОРОТКИ КРОВИ БОЛЬНЫХ ПУЗЫРЧАТКОЙ
CN105510595A (zh) * 2015-12-01 2016-04-20 邹检平 基于量子点CdTe检测人血清中VEGF浓度的试剂盒及其使用方法
CN109477843A (zh) 2016-07-15 2019-03-15 豪夫迈·罗氏有限公司 用于检测总vegf-a的水平的方法和手段
CN107167588A (zh) * 2017-03-28 2017-09-15 马杰 用于检测血清中血管内皮生长因子的抗体及试剂盒
RU2732013C1 (ru) * 2019-12-11 2020-09-10 Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами
CN111044734A (zh) * 2019-12-30 2020-04-21 上海复星长征医学科学有限公司 一种用于检测血管内皮生长因子的检测试剂盒及其制备方法和使用方法
KR102676458B1 (ko) 2021-05-20 2024-06-19 대한민국 보툴리눔 독소 a에 특이적인 항체, 이를 생산하는 하이브리도마 세포주, 및 이를 이용한 보툴리눔 독소 a 진단 키트
CN117805397A (zh) * 2024-02-29 2024-04-02 军科正源（北京）药物研究有限责任公司 检测游离vegf的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) * 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
DE19532347A1 (de) 1995-09-04 1997-03-06 Bayer Ag 4-Thiocarbamoyl-1-(3-pyrazolyl)-pyrazole
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
JP3591264B2 (ja) * 1997-12-24 2004-11-17 富士レビオ株式会社 Ｖｅｇｆ１２１特異的モノクローナル抗体及び測定方法
US7078382B1 (en) * 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
IL149171A0 (en) * 1999-11-16 2002-11-10 Genentech Inc Elisa for vegf
RU2271010C2 (ru) * 2004-03-31 2006-02-27 Общество с ограниченной ответственностью "Фирма МонА" Способ иммуноферментного анализа для определения фактора виллебранда, моноклональное антитело к фактору виллебранда (варианты) и штамм гибридных культивируемых клеток животных mus. musculus l. - продуцент моноклональных антител к фактору виллебранда (варианты)
CA2602963A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
CN101523220B (zh) 2006-10-04 2016-09-21 健泰科生物技术公司 针对vegf的elisa

Also Published As

Publication number Publication date
CA2663012C (en) 2017-06-27
RS53387B (sr) 2014-10-31
EP2069798A2 (en) 2009-06-17
RU2014104113A (ru) 2015-08-10
CN101523220B (zh) 2016-09-21
RU2517301C2 (ru) 2014-05-27
HRP20140675T1 (hr) 2014-10-10
JP2010506171A (ja) 2010-02-25
ES2584322T3 (es) 2016-09-27
EP3103812B1 (en) 2021-07-28
RU2009116611A (ru) 2010-11-10
EP2457929A1 (en) 2012-05-30
US9625462B2 (en) 2017-04-18
TW200823233A (en) 2008-06-01
AR063125A1 (es) 2008-12-30
US9146245B2 (en) 2015-09-29
WO2008060777A2 (en) 2008-05-22
JP6025294B2 (ja) 2016-11-16
HUE030082T2 (en) 2017-04-28
US20100255515A1 (en) 2010-10-07
EP3103812A1 (en) 2016-12-14
HK1130090A1 (en) 2009-12-18
AR107561A2 (es) 2018-05-09
PL2069798T3 (pl) 2014-09-30
KR101720887B1 (ko) 2017-03-28
BRPI0715239A2 (pt) 2013-06-25
WO2008060777A3 (en) 2008-07-10
US20160033517A1 (en) 2016-02-04
DK2069798T3 (da) 2014-06-16
KR20150038444A (ko) 2015-04-08
AU2007319654A1 (en) 2008-05-22
US8449885B2 (en) 2013-05-28
EP2069798B1 (en) 2014-04-16
CN103454434A (zh) 2013-12-18
NZ613646A (en) 2015-03-27
US20080227119A1 (en) 2008-09-18
PL2457929T3 (pl) 2016-12-30
HK1232236A1 (en) 2018-01-05
SI2069798T1 (sl) 2014-07-31
CN101523220A (zh) 2009-09-02
DK2457929T3 (en) 2016-09-05
HK1168361A1 (en) 2012-12-28
IL197374A (en) 2016-11-30
CN103454434B (zh) 2016-08-10
MX342791B (es) 2016-10-12
TWI541251B (zh) 2016-07-11
EP2457929B1 (en) 2016-06-08
TWI429654B (zh) 2014-03-11
IL197374A0 (en) 2009-12-24
CA2663012A1 (en) 2008-05-22
PT2069798E (pt) 2014-06-24
US20170276683A1 (en) 2017-09-28
TW201406778A (zh) 2014-02-16
KR20090091695A (ko) 2009-08-28
ES2470682T3 (es) 2014-06-24
AU2007319654B2 (en) 2013-09-12
SI2457929T1 (sl) 2016-09-30
US20130045495A1 (en) 2013-02-21
ZA200901518B (en) 2010-05-26
KR101551984B1 (ko) 2015-09-09

Similar Documents

Publication Publication Date Title
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
Fujita et al. Sex and age differences in the effect of obesity on incidence of hypertension in the Japanese population: a large historical cohort study
Mainous III et al. Grip strength as a marker of hypertension and diabetes in healthy weight adults
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
MX2007004079A (es) Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
MX378788B (es) Kits y ensayos de diagnóstico para la detección del receptor 1 de folato.
EP3708682A3 (en) Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
WO2006073682A3 (en) Diagnostic test
ES2531368T3 (es) Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno
Hou et al. White blood cell count in young adulthood and coronary artery calcification in early middle age: coronary artery risk development in young adults (CARDIA) study
Gupta et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders
Rahman Living with frailty: from assets and deficits to resilience
US20240081724A1 (en) Wearable point-of-care devices for assessing immune activity from interstitial fluid and methods of use thereof
CN101025415A (zh) 一种检测尿液中尿酸含量范围的试纸
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
CY1115197T1 (el) Elisa για vegf
Ettala et al. Erectile dysfunction cannot be used in primary screening of pre-diabetes
CY1112415T1 (el) Η πρωτεϊνη serum amyloid p-component (sap, samp) ως προγνωστικος και διαγνωστικος δεικτης για τον προγεννητικο ελεγχο της τρισωμιας 21 (συνδρομο down)
TH106073A (th) การทดสอบวิเคราะห์ elisa สำหรับตรวจหา vegf
DE502005003903D1 (de) Diagnose von sepsis durch selektive bestimmung der sod) in patientenproben
AB et al. Risk determinants of peripheral neuropathy in patients with type II diabetes mellitus attending follow-up clinics at Universiti Kebangsaan Malaysia Medical Center (UKMMC): a cross-sectional study
Zhang et al. Saliva: linking oral health with heart failure
RU2010143363A (ru) Способ диагностики функциональной диспепсии
Michaelis et al. Evaluation of the capillaroscopy using endothelin-1 as a marker of endothelial activation in microvascular injury and cutaneous ulcerations